Indian biologics market is estimated to grow at a CAGR of 10.2% during the forecast period. Some pivotal factors encouraging market growth include the rising prevalence of cancer and increasing launches of biologics in the country. A significant rise in cancer incidences has been reported in the country. As per the World Health Organization (WHO), in 2018, nearly 1.1 million new cancer incidences were reported in the country. In 2018, breast cancer accounted for 14.0%, lip, oral cavity (10.4%), cervix uteri (8.4%), lung (5.9%), stomach (5.0%), and other cancers (56.4%) of all new cancer incidences in the country. This, in turn, is driving the adoption of biologics which acts as an immune system substance that supports to augment the body’s ability to fight against cancer. Biologics comprises a comprehensive range of drugs that particularly target cancer cells, encourage the immune response, and support the recovery from cancer treatment. These drugs are normally utilized in combination with other therapies, including chemotherapy.

Visit for Global Biologics Market Report at: https://www.omrglobal.com/industry-reports/biologics-market

Indian biologics market is segmented based on product and application. Based on the product, the market is segmented into antibody therapeutics, vaccines, cell therapy, gene therapy, and others. Rising launches of antibody therapeutics are reflecting positively on the market growth. Cadila Pharmaceuticals Ltd., Biocon Ltd., and Cipla Ltd. are some players that are increasingly focusing on launching new monoclonal antibody therapies in the country. Based on application, the market is segmented into cancer, autoimmune diseases, infectious diseases, and others. 

Some key players in the market include AbbVie Inc., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Biocon Ltd., and Lupin Ltd. The market players are focusing on strategic initiatives, to gain a significant market share. For instance, in April 2019, Intas Pharmaceuticals declared the introduction of a ‘similar biologic’ of trastuzumab named Eleftha in India. This new drug claims that it will reduce the cost of breast cancer therapy by approximately 65%. It is a similar biologic of Herceptin (trastuzumab), Roche’s blockbuster breast cancer drug approved by the US FDA in September 1998 and by the European Medicines Agency (EMA) in August 2000. Herceptin is aimed to treat breast and gastric cancers.

Research Methodology

The market study of the Indian biologics market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Indian Biologics Market Research and Analysis by Product
2. Indian Biologics Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the Indian biologics market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the Indian biologics market.
• Insights about market determinants that are stimulating Indian biologics market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.